医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
2期
213-215
,共3页
王景麟%袁凤山%杨润乔%郑滨珠
王景麟%袁鳳山%楊潤喬%鄭濱珠
왕경린%원봉산%양윤교%정빈주
糖尿病 ,2型%受体 ,胰岛素%干细胞%大鼠
糖尿病 ,2型%受體 ,胰島素%榦細胞%大鼠
당뇨병 ,2형%수체 ,이도소%간세포%대서
Diabetes Mellitus,Type 2%Receptor,Insulin%Stem Cells%Rats
【目的】探讨自体干细胞激活疗法对2型糖尿病(T2DM )大鼠的降糖作用和对红细胞膜胰岛素受体数目及亲和力的影响。【方法】将实验大鼠分为健康对照组(NC组),糖尿病对照组(DC组),干细胞激活疗法治疗组(M I组),MI组给予rhG-CSF 3μg/(kg · d)隔日一次皮下注射,给予rhG-CSF d2开始每日行促肝细胞生长素3 mg/(kg · d)腹腔注射及烟酰胺100 mg/(kg · d)灌胃,连续28 d;NC组和DC组大鼠给予同体积生理盐水隔日一次皮下注射, d2开始每日给予同体积5%葡萄糖加中和量胰岛素腹腔注射、高压灭菌水灌胃,持续4周。实验结束后测定各组大鼠空腹血糖、空腹胰岛素、红细胞膜胰岛素受体数目和亲和力。【结果】造模后,与NC组对比,DC组、M I组大鼠空腹血糖、胰岛素抵抗指数(HOMA-IR)显著升高( P<0.01);MI组较DC组血糖值下降33.95%,HOMA-IR显著降低( P<0.05);DC组红细胞膜胰岛素受体数目较 NC组显著降低( P<0.05),MI组较DC组显著升高( P<0.05),三组间红细胞膜胰岛素受体亲和力无显著差异( P>0.05)。【结论】rh-CSF联合促肝细胞生长素和烟酰胺治疗可降低T2DM大鼠高血糖,并改善其胰岛素抵抗作用,其机制可能与提高细胞膜胰岛素受体数目相关。
【目的】探討自體榦細胞激活療法對2型糖尿病(T2DM )大鼠的降糖作用和對紅細胞膜胰島素受體數目及親和力的影響。【方法】將實驗大鼠分為健康對照組(NC組),糖尿病對照組(DC組),榦細胞激活療法治療組(M I組),MI組給予rhG-CSF 3μg/(kg · d)隔日一次皮下註射,給予rhG-CSF d2開始每日行促肝細胞生長素3 mg/(kg · d)腹腔註射及煙酰胺100 mg/(kg · d)灌胃,連續28 d;NC組和DC組大鼠給予同體積生理鹽水隔日一次皮下註射, d2開始每日給予同體積5%葡萄糖加中和量胰島素腹腔註射、高壓滅菌水灌胃,持續4週。實驗結束後測定各組大鼠空腹血糖、空腹胰島素、紅細胞膜胰島素受體數目和親和力。【結果】造模後,與NC組對比,DC組、M I組大鼠空腹血糖、胰島素牴抗指數(HOMA-IR)顯著升高( P<0.01);MI組較DC組血糖值下降33.95%,HOMA-IR顯著降低( P<0.05);DC組紅細胞膜胰島素受體數目較 NC組顯著降低( P<0.05),MI組較DC組顯著升高( P<0.05),三組間紅細胞膜胰島素受體親和力無顯著差異( P>0.05)。【結論】rh-CSF聯閤促肝細胞生長素和煙酰胺治療可降低T2DM大鼠高血糖,併改善其胰島素牴抗作用,其機製可能與提高細胞膜胰島素受體數目相關。
【목적】탐토자체간세포격활요법대2형당뇨병(T2DM )대서적강당작용화대홍세포막이도소수체수목급친화력적영향。【방법】장실험대서분위건강대조조(NC조),당뇨병대조조(DC조),간세포격활요법치료조(M I조),MI조급여rhG-CSF 3μg/(kg · d)격일일차피하주사,급여rhG-CSF d2개시매일행촉간세포생장소3 mg/(kg · d)복강주사급연선알100 mg/(kg · d)관위,련속28 d;NC조화DC조대서급여동체적생리염수격일일차피하주사, d2개시매일급여동체적5%포도당가중화량이도소복강주사、고압멸균수관위,지속4주。실험결속후측정각조대서공복혈당、공복이도소、홍세포막이도소수체수목화친화력。【결과】조모후,여NC조대비,DC조、M I조대서공복혈당、이도소저항지수(HOMA-IR)현저승고( P<0.01);MI조교DC조혈당치하강33.95%,HOMA-IR현저강저( P<0.05);DC조홍세포막이도소수체수목교 NC조현저강저( P<0.05),MI조교DC조현저승고( P<0.05),삼조간홍세포막이도소수체친화력무현저차이( P>0.05)。【결론】rh-CSF연합촉간세포생장소화연선알치료가강저T2DM대서고혈당,병개선기이도소저항작용,기궤제가능여제고세포막이도소수체수목상관。
[Objective]To explore the hypoglycemic effect of autologous stem cell activation therapy for type 2 diabetes mellitus(T2DM ) in rats and its impact on the number and affinity of insulin receptor on red cell mem-brane .[Methods] The experimental rats were divided into healthy control group (group NC) ,diabetes control group(group DC) and stem cell activation therapy group(group MI) .Group MI was given qod subcutaneous injec-tion of recombinant human granulocyte colony stimulating factor (rh-CSF) 3 μg/(kg · d) ,and then intraperitoneal injection of hepatocyte growth-promoting factor 3 mg/(kg · d) and intragastric administration of nicotinamide 100 mg/(kg · d) at d2 for continuous 28d .Group NC and group DC were given qod subcutaneous injection of isovol-ume normal saline ,and then intraperitoneal injection of isovolume 5% glucose and neutralized dose of insulin and intragastric administration of autoclaving water for continuous 4 weeks .Fasting blood glucose(FBG) ,fasting insu-lin ,number and affinity of insulin receptor on erythrocyte membrane in each group were measured after the experi-ment .[Results]After modeling ,FBG and insulin resistance(HOMA-IR) in group DC and group MI were signifi-cantly increased in comparison with group NC ( P < 0 .01) .Compared with group DC ,blood sugar in group MI was decreased by 33 .95% ,and HOMA-IR was decreased significantly( P<0 .05) .Compared with group NC ,the number of insulin receptor on erythrocyte membrane in group DC was decreased significantly ( P <0 .05) .Com-pared with group DC ,the number of insulin receptor on erythrocyte membrane in group MI was increased signifi-cantly( P <0 .05) .There was no significant difference in affinity of insulin receptor on erythrocyte membrane a-mong 3 groups( P>0 .05) .[Conclusion]The rh-CSF combined with hepatocyte growth-promoting factor and nico-tinamide can reduce the hyperglycemia of T 2DM in rats ,and improve insulin resistance .The mechanism may be associated with the increasing of the number of insulin receptor on cell membrane .